Art. 37 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 9×
1.

The marketing authorisation shall be refused if, after verification of the particulars and documents submitted in accordance with Article 31, it appears that:

(a)

the applicant has not properly or sufficiently demonstrated the quality, safety or efficacy of the veterinary medicinal product;

(b)

in the case of zootechnical veterinary medicinal products and performance enhancers, when the safety and welfare of the animals and/or consumer safety have not been sufficiently taken into account;

(c)

the withdrawal period recommended by the applicant is not long enough to ensure that foodstuffs obtained from treated animals do not contain residues which might constitute a health hazard for the consumer or is insufficiently substantiated;

(d)

the veterinary medicinal product is presented for a use prohibited under other Union provisions.

Authorisation shall likewise be refused if particulars or documents provided by the applicant in accordance with Article 31 are incorrect or if the labelling and package leaflets proposed by the applicant are not in accordance with Title V of Directive 2001/82/EC.

2.

The refusal of a Union marketing authorisation shall constitute a prohibition on the placing on the market of the veterinary medicinal product concerned throughout the Union.

3.

Information about all refusals and the reasons for them shall be made publicly accessible.

  • Ordonnance du président du Tribunal du 20 juillet 2016. MSD Animal Health Innovation GmbH et Intervet international BV contre Agence européeDecision

    … of an MA file for a veterinary medicinal product, the applicants’ claim that those texts — namely, inter alia, Articles 36, 37(3), 38(3), 57(1), point l, 57(2), 76 and 80 of Regulation No 726/2004 and Articles 13 and 76 of Directive …

    20 Jul 2016 · 62015TO0729

  • Judgment of the General Court (Second Chamber, Extended Composition) of 5 February 2018. Pari Pharma GmbH v European Medicines Agency.Decision

    Articles 11, 12, 36 and 37(3) of Regulation No 726/2004 also reflect the legislature’s intention that the MA procedure should be transparent, even where that procedure does not result in a decision or leads to a decision refusing MA. …

    5 Feb 2018 · 62015TJ0235

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    Articles 11, 12, 36 and 37(3) of Regulation No 726/2004 also reflect the legislature’s intention that the MA procedure should be transparent, even where that procedure does not result in a decision or leads to a decision refusing MA. …

    5 Feb 2018 · 62015TJ0718

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v MSD Animal Health Innovation GmbH and Intervet iDecision

    The existence of such a presumption follows from the system established by the sector-specific legislation applicable to marketing authorisation for veterinary medicinal products, in particular by Article 36, Article 37(3), Article 38(3) …

    1 Mar 2017 · 62016CO0512

  • Judgment of the General Court (Second Chamber) of 5 February 2018. MSD Animal Health Innovation GmbH and Intervet international BV v EuropeaDecision

    Articles 11, 12, 36 and 37(3) of Regulation No 726/2004 also reflect the legislature’s intention that the MA procedure should be transparent, even where that procedure does not result in a decision or leads to a decision refusing MA. …

    5 Feb 2018 · 62015TJ0729

  • Regulation (EU) 2019/5Lawamends

  • Regulation (EU) 2022/839Law

    … 1, член 34, параграф 1, буква в), член 34, параграф 4, буква д) и член 37, параграф 1, втора алинея от Регламент (ЕО) № 726/2004 в редакцията му, …

  • Judgment of the General Court (Second Chamber) of 25 September 2018. Amicus Therapeutics UK Ltd and Amicus Therapeutics, Inc. v European MedDecision

    Articles 11, 12, 36 and 37(3) of Regulation No 726/2004 also reflect the legislature’s intention that the marketing authorisation procedure should be transparent, even where that procedure does not result in a decision or leads to a …

    25 Sep 2018 · 62017TJ0033

  • Opinion of Advocate General Hogan delivered on 11 September 2019. MSD Animal Health Innovation GmbH and Intervet International BV v EuropeanDecision

    The wording of the first paragraph of Article 73 of Regulation 726/2004 is broad and unqualified. The fact that certain information has to be published proactively [See Article 35(6), Article 36, Article 37(3) and Article 38(2) and (3) of …

    11 Sep 2019 · 62018CC0178